Bio-Optronics is a provider of software to healthcare organizations. The company’s product suite includes Clinical Conductor, a leading Clinical Trial Management System (CTMS), Momentum, which enables fast, automated and accurate medical staff scheduling, and Biopoint, which enhances patient safety and streamlines patient workflow. Customers include leading hospital systems, clinical research sites and organizations, medical groups, and the Department of Veterans Affairs.
In March 2021, Mainsail portfolio company, Bio-Optronics was acquired by Advarra, a market leader in regulatory review solutions, research quality and compliance consulting services and clinical site technologies. Mainsail invested in Bio-Optronics in late 2017.
Chris Cassidy and Michael Anderson of Mainsail Partners sat down with Dan Kerpelman, the Founder and CEO of Bio-Optronics, to discuss the partnership and the number of key initiatives that were achieved to help the company grow.
Certain statements about Mainsail Management Company, LLC (“Mainsail” or “Mainsail Partners”) made by portfolio company executives herein are intended to illustrate Mainsail’s business relationship with such persons, including with respect to Mainsail’s facilities as a business partner, rather than Mainsail’s capabilities or expertise with respect to investment advisory services. Portfolio company executives were not compensated in connection with their participation, although they generally receive compensation and investment opportunities in connection with their portfolio company roles, and in certain cases are also owners of portfolio company securities and/or investors in Mainsail-sponsored vehicles. Such compensation and investments subject participants to potential conflicts of interest in making the statements herein.
This case study has been prepared solely for informational purposes and does not constitute an offer to sell or the solicitation of an offer to purchase any security. The information in this case study is not presented with a view to providing investment advice with respect to any security, or making any claim as to the past, current or future performance thereof, and Mainsail expressly disclaims the use of this case study for such purposes. The information herein is not and may not be relied on in any manner as, legal, tax, business or investment advice.
The portfolio company identified in this case study was selected as representative example that clarifies and typifies Mainsail’s investment approach and was not selected based on the performance of such investment. It may not be representative of any current or future investments. The performance of these investments is not necessarily indicative of the performance of all investments made or recommended by Mainsail Partners. It should not be assumed that such investments were or will be profitable or that any portfolio company investments made in the future will equal the performance of the companies identified herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. Past performance is not indicative of future results.
Certain information contained in this case study has been obtained from published and non‐published sources prepared by other parties, which in certain cases have not been updated through the date hereof. While such information is believed to be reliable for the purposes of this case study, neither Mainsail nor the author assume any responsibility for the accuracy or completeness of such information and such information has not been independently verified by either of them. The case study will not be updated or otherwise revised to reflect information that subsequently becomes available, or circumstances existing or changes occurring after the date hereof, or for any other reason.
No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained in the enclosed materials by Mainsail and no liability is accepted by such persons for the accuracy or completeness of any such information or opinions. For additional disclosures, please click here.
